



STEFAN J. KLAUBER
DAVID A. JACKSON
STEVE S. CHA
VALETA A. GREGG, PH.D.*
STEPHEN GIGANTE
LAWRENCE D. MANDEL*
CATHERINE ROSEMAN SMITH*

* BAR OTHER THAN N.J.
* COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.
MICHAEL A. YAMIN, PH.D.

SCIENTIFIC ADVISOR

VERONICA M. MALLON, PH.D.

KLAUBER & JACKSON
ATTORNEYS AT LAW
CONTINENTAL PLAZA
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

PATENT, TRADEMARK AND
COPYRIGHT CAUSES

(201) 487-5800

FACSIMILE: (201) 343-1684

WWW.KJILAW.COM

email: info@kjiplaw.com

April 10, 2002

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Attention: Box Missing Parts
Application Processing Division
Special Processing and Correspondence Branch

Re: U.S. Patent Application
Applicant(s) : Herath Mudiyanseelage Athula Chandrasiri
Serial No. : Herath *et al*
Filed : 09/988,493
Title : November 20, 2001
PROTEINS, GENES AND THEIR USE
FOR DIAGNOSIS AND TREATMENT OF
BREAST CANCER
Docket No. : 2543-1-024

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to BOX MISSING PARTS, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on April 10, 2002.

Betty Schultz
(Name of Depositor)

Betty Schultz 4/10/02
(Signature and Date)

SUBMISSION OF MISSING PARTS OF APPLICATION
UNDER 37 CFR 1.53(d)

Sir:

Responsive to the Notice to File Missing Parts of Application dated December 10, 2001, (copy enclosed) under 37 CFR 1.53(d), Applicants submit herewith the following:

1. A combined Declaration and Power of Attorney making reference to the above-identified

ASSISTANT COMMISSIONER FOR PATENTS

April 10, 2002

Page - 2 -

Docket No.: 2543-1-024

- application, and in compliance with 37 CFR 1.63;
2. A Petition for a Two-Month Extension of Time under 37 CFR 1.136;
 3. An Associate Power of Attorney;
 4. A check in the amount of \$3,070.00, covering the following:


(a)	Filing Fee under 37 CFR 1.16 (including multiple dependent claims)	:	2,540.00
(b)	Surcharge under 37 CFR 1.16	:	130.00
(c)	Fee for Two-Month Extension of time under 37 CFR 1.17	:	400.00

The time set for this response is April 10, 2002 with a Two-Month Extension of Time.

A correct Filing Receipt reflecting the above and attached information is requested.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153.

Respectfully submitted,


VALETA A. GREGG
Attorney for Applicant(s)
Registration No. 35,127

VAG/bls
Enclosures



FILE COPY *pt*

PATENT
25431-02

TECH CENTER 1600/2900

AUG 28 2002

RECEIVED

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Herath Mudiyansele Athula Chandrasiri Herath *et al*
SERIAL NO. : 09/988,493
FILED : November 20, 2001
FOR : PROTEINS, GENES AND THEIR USE FOR DIAGNOSIS AND
TREATMENT OF BREAST CANCER

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to BOX ISSUE FEE, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on April 10, 2002.

Betty Schultz
(Name of Depositor)

Betty Schultz 4/10/02
(Signature and Date)

REQUEST FOR CORRECTED FILING RECEIPT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Attention: Office of Initial Patent Examination's Customer
Service Center

Dear Sir:

Applicants hereby request that a corrected Formal Filing Receipt (PTO-103X) be issued to add foreign priority data in the above-identified Application.

Please add the following priority data under "Foreign Applications":

--Application No. 0006695.1, filed on March 20, 2000 in Great Britain

Application No. 0007265.2, filed on March 20, 2000 in Great Britain--

as it appears on the first page of the Published PCT Application and on the Declaration and


Power of Attorney, copies enclosed for your reference.

A copy of the filing receipt with the requested correction marked in red is also enclosed.

PATENT
2543-1-024

Applicants request that the records of the U.S. Patent and Trademark Office be corrected
to reflect the priority applications filed in Great Britain.

Respectfully submitted,



Valeta A. Gregg
Attorney for Applicant
Registration No. 35,127

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800

Date: April 10, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED
AUG 28 2002


TECH CENTER 1600/2500
COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/988,493	11/20/2001	1743	0.00	2543-1-024	2	44	12

CONFIRMATION NO. 8554

23565
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

FILING RECEIPT



OC000000007179026

Date Mailed: 12/10/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Herath Mudiyanseelage Athula Chandrasiri Herath, Abingdon, UNITED KINGDOM;
Michael John O'Hare, London, UNITED KINGDOM;
Martin John Page, Abingdon, UNITED KINGDOM;
Rajesh Bhikhu Parekh, Nr. Wendlebury, UNITED KINGDOM;
Michael Derek Waterfield, London, UNITED KINGDOM;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF PCT/GB01/01219 03/20/2001

Foreign Applications GB Application NO. 0006695.1, filed March 20, 2000
GB Application NO. 0007265.2, filed March 20, 2000
If Required, Foreign Filing License Granted 12/10/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No


DEC

Title

Proteins, genes and their use for diagnosis and treatment of breast cancer

Preliminary Class

436



LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

RECEIVED
AUG 28 2002
TECH CENTER 1600/2300

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

#3



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/988,493	11/20/2001	Herath Mudiyansele Athula Chandrasiri Herath	2543-1-024

CONFIRMATION NO. 8554

FORMALITIES LETTER



OC000000007179027

23565

KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

Adjustment date: 05/20/2002 MPASASD 0012244500
04/10/2002 HBERHE 00000046 09988493
04 FC:103 -594.00 09
05 FC:102 -324.00 09
06 FC:104 -280.00 09

Repln. Ref: 05/20/2002 MPASASD 0012244500
DAO:111153 Page/Number:09988493
FC: 704 0610.00 09

Date Mailed: 12/10/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

06/20/2002 MPASASD 00000017 09988493

FILED UNDER 37 CFR 1.53(b)

01 FC:102 756.00 09
02 FC:103 432.00 09

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 740 to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$1188.
 - \$432 for 24 total claims over 20.
 - \$756 for 9 independent claims over 3.
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.136(d) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 2058.

04/10/2002 HBERHE 00000046 09988493
02 FC:101 740.00 09
03 FC:105 130.00 09
04 FC:103 594.00 09
05 FC:102 324.00 09
06 FC:104 280.00 09
07 FC:998 2.00 09

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S.